

# Peter H GÃ|de

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3093052/publications.pdf>

Version: 2024-02-01

50  
papers

9,787  
citations

361413

20  
h-index

206112

48  
g-index

52  
all docs

52  
docs citations

52  
times ranked

7641  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Bolus Calculation and Advanced Carbohydrate Counting in Type 2 Diabetes: A Randomized Clinical Trial. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 95-103.	4.4	10
2	Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. <i>PLoS ONE</i> , 2021, 16, e0244402.	2.5	20
3	Prevalence of urinary incontinence among women with diabetes in the Lolland-Falster Health Study, Denmark. <i>Neurourology and Urodynamics</i> , 2021, 40, 855-867.	1.5	10
4	The economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in Denmark. <i>Current Medical Research and Opinion</i> , 2021, 37, 949-956.	1.9	8
5	Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2374-2384.	4.4	9
6	Interventions involving own treatment choice for people living with coexisting severe mental illness and type 1 or 2 diabetes: A scoping review. <i>Diabetic Medicine</i> , 2021, 38, e14626.	2.3	4
7	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020418.	3.7	12
8	Hypothyroidism and urinary incontinence: Prevalence and association in a Danish, female sample from the Lolland-Falster Health study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 264, 232-240.	1.1	0
9	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. <i>International Journal of Cardiovascular Imaging</i> , 2021, , 1.	1.5	6
10	Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 61-65.	2.9	21
11	Cardiac perfusion, structure, and function in type 2 diabetes mellitus with and without diabetic complications. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 887-895.	1.2	28
12	Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 184.	6.8	21
13	Short-term societal economic burden of first-incident type 2 diabetes-related complications " a nationwide cohort study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 577-586.	1.4	5
14	Reduced Myocardial Perfusion Reserve in Type 2 Diabetes Is Caused by Increased Perfusion at Rest and Decreased Maximal Perfusion During Stress. <i>Diabetes Care</i> , 2020, 43, 1285-1292.	8.6	25
15	Mitochondrial energetics and contents evaluated by flow cytometry in human maternal and umbilical cord blood. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 351-359.	1.2	3
16	Monitoring patients with acute dyspnoea with a serial focused ultrasound of the heart and the lungs (MODUS): a protocol for a multicentre, randomised, open-label, pragmatic and controlled trial. <i>BMJ Open</i> , 2020, 10, e034373.	1.9	2
17	Hypoglycaemia and its management in primary care setting. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3332.	4.0	8
18	Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics. <i>Cardiovascular Diabetology</i> , 2020, 19, 158.	6.8	14

#	ARTICLE	IF	CITATIONS
19	Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study. <i>Diabetologia</i> , 2019, 62, 1575-1580.	6.3	19
20	Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. <i>Diabetes Therapy</i> , 2019, 10, 1297-1317.	2.5	23
21	A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study. <i>Diabetologia</i> , 2019, 62, 147-155.	6.3	16
22	Subclinical hypothyroidism: A common finding in adult patients with cyanotic congenital heart disease. <i>Congenital Heart Disease</i> , 2018, 13, 263-270.	0.2	4
23	Indicator of RNA oxidation in urine for the prediction of mortality in patients with type 2 diabetes and microalbuminuria: A post-hoc analysis of the Steno-2 trial. <i>Free Radical Biology and Medicine</i> , 2018, 129, 247-255.	2.9	9
24	Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1133-1140.	2.3	9
25	Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. <i>Diabetologia</i> , 2018, 61, 1724-1733.	6.3	66
26	A Cost Analysis of Intensified vs. Conventional Multifactorial Therapy of Patients with Type 2 Diabetes – The Steno 2 Study. <i>Diabetes</i> , 2018, 67, 162-OR.	0.6	1
27	Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. <i>Kidney International</i> , 2017, 91, 982-988.	5.2	80
28	Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. <i>Diabetologia</i> , 2016, 59, 2298-2307.	6.3	378
29	Intervención sobre múltiples factores de riesgo para prevenir la enfermedad cardiovascular. Un enfoque basado en la evidencia. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 173-174.	1.2	3
30	Multiple Risk Factor Intervention to Prevent Cardiovascular Disease. A High Powered and Evidence Based Approach. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2011, 64, 173-174.	0.6	1
31	A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes. <i>PLoS Genetics</i> , 2010, 6, e1000842.	3.5	81
32	Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 358, 580-591.	27.0	3,037
33	Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1510-1515.	8.6	130
34	Intensive glucose control and cardiovascular disease in type 2 diabetes – should we change the recommended target for glycated hemoglobin? Commentary to ACCORD and ADVANCE trials. <i>Polish Archives of Internal Medicine</i> , 2008, 118, 619-621.	0.4	2
35	Rosiglitazone monotherapy for type 2 diabetes mellitus – too soon to ADOPT?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 456-457.	2.8	0
36	Polymorphisms in the 3' UTR in the neurocalcin $\gamma$ gene affect mRNA stability, and confer susceptibility to diabetic nephropathy. <i>Human Genetics</i> , 2007, 122, 397-407.	3.8	57

#	ARTICLE	IF	CITATIONS
37	PROactive study. <i>Lancet, The</i> , 2006, 367, 23-24.	13.7	13
38	Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. <i>Diabetologia</i> , 2005, 48, 156-163.	6.3	89
39	Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2784-2788.	0.7	188
40	Target intervention against multiple risk markers to reduce cardiovascular disease in patients with type 2 diabetes. <i>Annals of Medicine</i> , 2004, 36, 355-366.	3.8	15
41	Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2003, 348, 383-393.	27.0	3,894
42	Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 19-23.	3.4	65
43	Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 539-542.	0.7	16
44	Limited impact of lifestyle education in patients with Type 2 diabetes mellitus and microalbuminuria: results from a randomized intervention study. <i>Diabetic Medicine</i> , 2001, 18, 104-108.	2.3	36
45	Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. <i>Diabetic Medicine</i> , 2001, 18, 756-760.	2.3	107
46	Studies of the variability of the hepatocyte nuclear factor-1 $\hat{2}$ (HNF-1 $\hat{2}$ / TCF2) and the dimerization cofactor of HNF-1 (DcoH / PCBD) genes in relation to type 2 diabetes mellitus and $\hat{2}$ -cell function. <i>Human Mutation</i> , 2001, 18, 356-357.	2.5	8
47	Mutation analysis of peroxisome proliferator-activated receptor- $\hat{3}$ coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. <i>Diabetologia</i> , 2001, 44, 2220-2226.	6.3	288
48	Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2028-2033.	0.7	14
49	Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. <i>Diabetes Care</i> , 2000, 23, 1742-1745.	8.6	21
50	Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. <i>Lancet, The</i> , 1999, 353, 617-622.	13.7	911